PDT and Iridex formalize photodynamic therapy device co-development pact.
This article was originally published in The Gray Sheet
Executive Summary
PDT, IRIDEX FORMALIZE PHOTODYNAMIC THERAPY DEVICE CO-DEVELOPMENT PACT with a May 28 agreement, PDT states. The two firms began working together about 12 months ago under an informal agreement to develop a light source to activate PDT's photodynamic therapy drug candidate, SnET2 (tin ethyl etiopurpurin), for the treatment of choroidal neovascularization associated with advanced age-related macular degeneration (AMD). Phase I/II clinical studies of the combination product commenced May 8.